HLA genotypes and rubella vaccine immune response: Additional evidence

Vaccine

Volumn 32, Issue 33, 2014, Pages 4206-4213

  Ovsyannikova, Inna G ^a   Pankratz, V Shane ^a   Larrabee, Beth R ^a   Jacobson, Robert M ^a   Poland, Gregory A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Cytokines; HLA antigens; Neutralizing antibodies; Rubella vaccine

Indexed keywords

GAMMA INTERFERON; HLA DPB1 ANTIGEN; HLA DQA1 ANTIGEN; HLA DQB1 ANTIGEN; HLA DRB1 ANTIGEN; INTERLEUKIN 6; NEUTRALIZING ANTIBODY; RUBELLA VACCINE; HLA A ANTIGEN; HLA B27 ANTIGEN; HLA DP ANTIGEN; HLA-A*31:01 ANTIGEN; HLA-B*27:05 ANTIGEN; HLA-DPB1*04:01 ANTIGEN; VIRUS ANTIBODY;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY TITER; ARTICLE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; GENOTYPE; HLA SYSTEM; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; NORMAL HUMAN; PHENOTYPE; PRIORITY JOURNAL; ADOLESCENT; BLOOD; CHILD; FEMALE; GENETICS; HUMORAL IMMUNITY; MALE; MIDDLE AGED; YOUNG ADULT;

ADOLESCENT; ADULT; ANTIBODIES, NEUTRALIZING; ANTIBODIES, VIRAL; CHILD; FEMALE; GENOTYPE; HLA-A ANTIGENS; HLA-B27 ANTIGEN; HLA-DP BETA-CHAINS; HUMANS; IMMUNITY, HUMORAL; MALE; MIDDLE AGED; RUBELLA VACCINE; YOUNG ADULT;

EID: 84903467589     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2014.04.091     Document Type: Article

References (44)

1. Plotkin S.A. The history of rubella and rubella vaccination leading to elimination. Clin Infect Dis 2006, 43(Suppl. 3):S164-S168.
2. LeBaron C.W., Forghani B., Matter L., Reef S.E., Beck C., Bi D., et al. Persistence of rubella antibodies after 2 doses of measles-mumps-rubella vaccine. J Infect Dis 2009, 200(6):888-899.
3. Baer G., Bonhoeffer J., Schaad U.B., Heininger U. Seroprevalence and immunization history of selected vaccine preventable diseases in medical students. Vaccine 2005, 23(16):2016-2020.
4. Tan P.L., Jacobson R.M., Poland G.A., Jacobsen S.J., Pankratz S.V. Twin studies of immunogenicity - determining the genetic contribution to vaccine failure. Vaccine 2001, 19:2434-2439.
5. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., O'Byrne M.M., Poland G.A. Replication of rubella vaccine population genetic studies: validation of HLA genotype and humoral response associations. Vaccine 2009, 27(49):6926-6931.
6. Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., Jacobson R.M., Poland G.A., Extended L.T.A., et al. HLA gene haplotypes and their association with rubella vaccine-induced immunity. PLoS ONE 2010, 5(7):e11806.
7. Ovsyannikova I.G., Dhiman N., Haralambieva I.H., Vierkant R.A., O'Byrne M.M., Jacobson R.M., et al. Rubella vaccine-induced cellular immunity: evidence of associations with polymorphisms in the Toll-like, vitamin A and D receptors, and innate immune response genes. Hum Genet 2010, 127:207-221.
8. Pankratz V.S., Vierkant R.A., O'Byrne M.M., Ovsyannikova I.G., Poland G.A. Associations between SNPs in candidate immune-relevant genes and rubella antibody levels: a multigenic assessment. BMC Immunol 2010, 11(1):48.
9. Poland G.A., Kennedy R.B., McKinney B.A., Ovsyannikova I.G., Lambert N.D., Jacobson R.M., et al. Vaccinomics, adversomics, and the immune response network theory: Individualized vaccinology in the 21st century. Semin Immunol 2013, 25(2):89-103.
10. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., Vierkant R.A., Jacobson R.M., Ryan M.A., et al. Gender effects on humoral immune responses to smallpox vaccine. Vaccine 2009, 27(25-26):3319-3323.
11. Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., Jacobson R.M., Poland G.A. Human leukocyte antigen genotypes in the genetic control of adaptive immune responses to smallpox vaccine. J Infect Dis 2011, 203(11):1546-1555.
12. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., Poland G.A. The contribution of HLA class I antigens in immune status following two doses of rubella vaccination. Hum Immunol 2004, 65:1506-1515.
13. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Jacobsen S.J., Pankratz V.S., Poland G.A. Human leukocyte antigen class II alleles and rubella-specific humoral and cell-mediated immunity following measles-mumps-rubella-II vaccination. J Infect Dis 2005, 191(4):515-519.
14. Haralambieva I.H., Dhiman N., Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., Jacobson R.M., et al. 2'-5'-Oligoadenylate synthetase single-nucleotide polymorphisms and haplotypes are associated with variations in immune responses to rubella vaccine. Hum Immunol 2010, 71(4):383-391.
15. Chen M.H., Zhu Z., Zhang Y., Favors S., Xu W.B., Featherstone D.A., et al. An indirect immunocolorimetric assay to detect rubella virus infected cells. J Virol Methods 2007, 146(1-2):414-418.
16. Cleveland W.S., Gross E., Shyu W.M. Local regression models. Statistical models 1992, Wadsworth & Brooks/Cole. J.M. Chambers, T.J. Hastie (Eds.).
17. Ovsyannikova I.G., Ryan J.E., Vierkant R.A., O'Byrne M.M., Jacobson R.M., Poland G.A. Influence of host genetic variation on rubella-specific T cell cytokine responses following rubella vaccination. Vaccine 2009, 27:3359-3366.
18. Dhiman N., Haralambieva I.H., Vierkant R.A., Pankratz V.S., Ryan E., Jacobson R.M., et al. Predominant inflammatory cytokine secretion pattern in response to two doses of live rubella vaccine in health vaccinees. Cytokine 2010, 50:24-29.
19. Ovsyannikova I.G., Kennedy R.B., O'Byrne M., Jacobson R.M., Pankratz V.S., Poland G.A. Genome-wide association study of antibody response to smallpox vaccine. Vaccine 2012, 30(28):4182-4189.
20. Kennedy R.B., Ovsyannikova I.G., Pankratz V.S., Haralambieva I.H., Vierkant R.A., Jacobson R.M., et al. Genome-wide genetic associations with IFNgamma response to smallpox vaccine. Hum Genet 2012, 131(9):1433-1451.
21. Price A.L., Patterson N.J., Plenge R.M., Weinblatt M.E., Shadick N.A., Reich D. Principal components analysis corrects for stratification in genome-wide association studies. Nat Genet 2006, 38(8):904-909.
22. Poland G.A., Ovsyannikova I.G., Kennedy R.B., Haralambieva I.H., Jacobson R.M. Vaccinomics and a new paradigm for the development of preventive vaccines against viral infections. Omics 2011, 15(9):625-636.
23. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Personalized vaccines: the emerging field of vaccinomics. Expert Opin Biol Ther 2008, 8(11):1659-1667.
24. Poland G.A., Ovsyannikova I.G., Jacobson R.M. Application of pharmacogenomics to vaccines. Pharmacogenomics 2009, 10(5):837-852.
25. Harcourt G.C., Best J.M., Banatvala J.E. HLA antigens and responses to rubella vaccination. J Hyg 1979, 83:405-412.
26. Kato S., Kimura M., Takakura I., Sakakibara T., Inouye H., Tsuji K. Possible associations between HLA antigens and the immune responsiveness to attenuated rubella vaccine. Tissue Antigens 1978, 11:475-478.
27. Ovsyannikova I.G., Vierkant R.A., Pankratz V.S., O'Byrne M.M., Jacobson R.M., Poland G.A. HLA haplotype and supertype associations with cellular immune responses and cytokine production in healthy children after rubella vaccine. Vaccine 2009, 27:3349-3358.
28. Ovsyannikova I.G., Jacobson R.M., Ryan J.E., Dhiman N., Vierkant R.A., Poland G.A. Relationship between HLA polymorphisms and gamma interferon and interleukin-10 cytokine production in healthy individuals after rubella vaccination. Clin Vaccine Immunol 2007, 14(2):115-122.
29. Sorrentino R., Bockmann R.A., Fiorillo M.T. HLA-B27 and antigen presentation: at the crossroads between immune defense and autoimmunity. Mol Immunol 2014, 57(1):22-27.
30. Sheehan N.J. HLA-B27: what's new?. Rheumatology (Oxford) 2010, 49(4):621-631.
31. Boon A.C., De Mutsert G., Fouchier R.A., Sintnicolaas K., Osterhaus A.D., Rimmelzwaan G.F. Preferential HLA usage in the influenza virus-specific CTL response. J Immunol 2004, 172(7):4435-4443.
32. Neumann-Haefelin C., McKiernan S., Ward S., Viazov S., Spangenberg H.C., Killinger T., et al. Dominant influence of an HLA-B27 restricted CD8+ T cell response in mediating HCV clearance and evolution. Hepatology 2006, 43(3):563-572.
33. Brooks J.M., Murray R.J., Thomas W.A., Kurilla M.G., Rickinson A.B. Different HLA-B27 subtypes present the same immunodominant Epstein-Barr virus peptide. J Exp Med 1993, 178(3):879-887.
34. Neumann-Haefelin C. HLA-B27-mediated protection in HIV and hepatitis C virus infection and pathogenesis in spondyloarthritis: two sides of the same coin?. Curr Opin Rheumatol 2013, 25(4):426-433.
35. Ovsyannikova I.G., Jacobson R.M., Vierkant R.A., Pankratz S.V., Jacobsen S.J., Poland G.A. Associations between human leukocyte antigen (HLA) alleles and very high levels of measles antibody following vaccination. Vaccine 2004, 22:1914-1920.
36. Kennedy R.B., Ovsyannikova I.G., Vierkant R.A., Jacobson R.M., Poland G.A. Effect of human leukocyte antigen homozygosity on rubella vaccine-induced humoral and cell-mediated immune responses. Hum Immunol 2010, 71(2):128-135.
37. Wu T.W., Chu C.C., Ho T.Y., Chang Liao H.W., Lin S.K., Lin M., et al. Responses to booster hepatitis B vaccination are significantly correlated with genotypes of human leukocyte antigen (HLA)-DPB1 in neonatally vaccinated adolescents. Hum Genet 2013, 132(10):1131-1139.
38. Nishida N., Sawai H., Matsuura K., Sugiyama M., Ahn S.H., Park J.Y., et al. Genome-wide association study confirming association of HLA-DP with protection against chronic hepatitis B and viral clearance in Japanese and Korean. PLos ONE 2012, 7(6):e39175.
39. Thomas R., Thio C.L., Apps R., Qi Y., Gao X., Marti D., et al. A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol 2012, 86(12):6979-6985.
40. Desombere I., Willems A., Leroux-Roels G. Response to hepatitis B vaccine: multiple HLA genes are involved. Tissue Antigens 1998, 51(6):593-604.
41. Chicz R.M., Graziano D.F., Trucco M., Strominger J.L., Gorga J.C. HLA-DP2 self peptide sequences and binding properties. J Immunol 1997, 159:4935-4949.
42. Ovsyannikova I.G., Ryan J.E., Vierkant R.A., Pankratz S.V., Jacobson R.M., Poland G.A. Immunologic significance of HLA class I genes in measles virus-specific IFN-gamma and IL-4 cytokine immune responses. Immunogenetics 2005, 57(11):828-836.
43. Borghan M.A., Oka S., Takiguchi M. Identification of HLA-A*3101-restricted cytotoxic T-lymphocyte response to human immunodeficiency virus type 1 (HIV-1) in patients with chronic HIV-1 infection. Tissue Antigens 2005, 66(4):305-313.
44. Chanock S.J., Manolio T., Boehnke M., Boerwinkle E., Hunter D.J., Thomas G., et al. Replicating genotype-phenotype associations. Nature 2007, 447(7145):655-660.